BioSpace News Archive

CVD Equipment Corporation (NASDAQ: CVV), a leading provider of chemical vapor deposition systems and materials, today announced its second quarter 2019 financial results.

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal quarter ended June 30, 2019.

Medpace Holdings, Inc. announced that it will present at the following investor conference in September

Fuse Medical, Inc. announced that it has filed its quarterly report on Form 10-Q for the second quarter ended June 30, 2019, with the United States Securities and Exchange Commission, on Monday, August 12, 2019.

Ironwood Pharmaceuticals, Inc. announced that, in connection with its previously announced offering of 0.75% Convertible Senior Notes due 2024 and 1.50% Convertible Senior Notes due 2026, the initial purchaser exercised in full its option to purchase $25 million aggregate principal amount of the 2024 Notes and $25 million aggregate principal amount of the 2026 Notes.

Terns Pharmaceuticals, Inc. announced the interim results of an ongoing Phase 1 clinical trial of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, being developed for the treatment of NASH.

Seven Bridges, the industry-leading bioinformatics solution provider, announced plans to expand operations into Novi Sad, Serbia in support of their growing customer base and to expedite product innovation.

Global digital therapeutics innovator DarioHealth Corp., reported financial and operational results for the second quarter ended June 30, 2019.

The aftermath of the deluge of prescription pain pills that flooded New Jersey and other states in the last decade continues to cause an increased need for addiction treatment services for opioid dependency.

Appnovation to drive international growth and expansion in partnership with the Canadian Business Growth Fund and UK-based BGF